Akebia Strikes $350m+ Asian Vadadustat Alliance
This article was originally published in PharmAsia News
Executive Summary
Mitsubishi Tanabe's agreement to acquire selected Asian rights to Akebia's vadadustat will boost the Japanese firm's existing presence in kidney disease while providing important funding for the US company's planned Phase III program with the novel anemia drug.